{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:01:32Z","timestamp":1772521292858,"version":"3.50.1"},"reference-count":42,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/130\/94"],"award-info":[{"award-number":["15\/130\/94"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical haemolytic uraemic syndrome is a rare disease (incidence: 0.4 cases per million per year) which, without treatment, is associated with high morbidity and mortality. Eculizumab, a monoclonal complement inhibitor, is an effective treatment but the optimal way to use this high-cost medication (\u00a3360,000 per year for an adult) has not been established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Establish the safety of eculizumab withdrawal and the effectiveness of a monitoring protocol to detect disease relapse and reintroduction of treatment if relapse occurs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Fifteen hospitals in the United Kingdom.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>SETS aHUS is a multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome using Bayes single arm analysis with a health economic analysis and qualitative study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients over 2 years of age with atypical haemolytic uraemic syndrome who were receiving eculizumab therapy for at least 6 months. Two study arms are described with 28 participants recruited to the withdrawal arm and 11 additional participants recruited to the standard of care arm of the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Withdrawal of eculizumab treatment and replacement with monitoring to assess disease activity with reintroduction of treatment if relapse occurs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>The primary outcome measure was to determine the safety of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome during the 2-year study period. Patients met a primary outcome of \u2018safety event occurred\u2019 if there was a permanent reduction in estimated glomerular filtration rate or requirement for renal replacement therapy or significant extra-renal manifestation of disease. The health economic analysis compared the cost and health outcomes on and off eculizumab treatment. The qualitative study explored the experiences of patients on living with atypical haemolytic uraemic syndrome and eculizumab treatment, views on withdrawing from treatment and the proposed monitoring plan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One of 28 patients (3.6%) who withdrew from treatment met a primary outcome. Based on the pre-study analysis plan, withdrawal from treatment is not associated with a greater risk to patients compared to remaining on treatment. Of 17 patients with an abnormality in complement regulation, 4 relapsed. Of 11 patients with no abnormality in complement regulation, 0 relapsed. It was possible, by monitoring and rapid patient access, to reintroduce eculizumab treatment when relapse was identified. Most patients welcomed the opportunity to withdraw from treatment but identified concerns about monitoring and the risk of relapse, informed by initial experience at presentation. Withdrawing a patient from treatment saves \u00a34.2M in healthcare costs (80 years time horizon).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-9\">\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Reflecting the low prevalence, participant numbers are low, particularly in the standard of care group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-10\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Withdrawal of eculizumab treatment with monitoring of disease activity exhibited a favourable safety profile compared to continuation of eculizumab, was acceptable to patients and carers and is associated with significant cost savings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-11\">\n                    <jats:title>Future work<\/jats:title>\n                    <jats:p>More real-world data should be generated by continued assessment of patients after treatment withdrawal including risk of relapse, renal outcomes, real-world economic analysis and a better understanding of communicating change to patients and carers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-12\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 15\/130\/94.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/gjns4701","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:25:27Z","timestamp":1751361927000},"page":"1-37","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-8865","authenticated-orcid":true,"given":"Andrew","family":"Bryant","sequence":"first","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5191-5804","authenticated-orcid":true,"given":"Jan","family":"Lecouturier","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7473-7318","authenticated-orcid":true,"given":"Giovany","family":"Orozco-Leal","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-0306","authenticated-orcid":true,"given":"Vicky","family":"Brocklebank","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-4297","authenticated-orcid":true,"given":"Sonya","family":"Carnell","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-0302","authenticated-orcid":true,"given":"Thomas J","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-3931","authenticated-orcid":true,"given":"Sarah","family":"Dunn","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-1347","authenticated-orcid":true,"given":"Sally A","family":"Johnson","sequence":"additional","affiliation":[{"name":"Great North Children\u2019s Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4718-0072","authenticated-orcid":true,"given":"David","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-0977","authenticated-orcid":true,"given":"Ciara A","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-1521","authenticated-orcid":true,"given":"Michal","family":"Malina","sequence":"additional","affiliation":[{"name":"Great North Children\u2019s Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4051-2620","authenticated-orcid":true,"given":"Emma K","family":"Montgomery","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5394-1267","authenticated-orcid":true,"given":"Colin R","family":"Muirhead","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9891-8279","authenticated-orcid":true,"given":"Yemi","family":"Oluboyede","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8429","authenticated-orcid":true,"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-0393","authenticated-orcid":true,"given":"Chris","family":"Weetman","sequence":"additional","affiliation":[{"name":"Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4867-6117","authenticated-orcid":true,"given":"Edwin","family":"Kwan Soon Wong","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2809-7804","authenticated-orcid":true,"given":"Len","family":"Woodward","sequence":"additional","affiliation":[{"name":"aHUS Alliance Global Action, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3743-2371","authenticated-orcid":true,"given":"Neil S","family":"Sheerin","sequence":"additional","affiliation":[{"name":"National Renal Complement Therapeutics Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2026,2]]},"reference":[{"key":"key2026030311253500_ref1-bib1","doi-asserted-by":"crossref","first-page":"101392","DOI":"10.1016\/j.lanepe.2025.101392","article-title":"Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial","volume":"56","author":"Bryant","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"key2026030311253500_ref2-bib2","doi-asserted-by":"crossref","first-page":"e054536","DOI":"10.1136\/bmjopen-2021-054536","article-title":"Safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome: protocol for a multicentre, open-label, prospective, single-arm study","volume":"12","author":"Dunn","year":"2022","journal-title":"BMJ Open"},{"key":"key2026030311253500_ref3-bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"key2026030311253500_ref4-bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"key2026030311253500_ref5-bib5","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2215\/CJN.03270906","article-title":"Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome","volume":"2","author":"Kavanagh","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"key2026030311253500_ref6-bib6","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.kint.2017.04.028","article-title":"Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland","volume":"92","author":"Brocklebank","year":"2017","journal-title":"Kidney Int"},{"key":"key2026030311253500_ref7-bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"key2026030311253500_ref8-bib8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"key2026030311253500_ref9-bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"key2026030311253500_ref10-bib10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"key2026030311253500_ref11-bib11","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"key2026030311253500_ref12-bib12","volume-title":"Assessment Report","author":"European Medicines Agency","year":"2011"},{"key":"key2026030311253500_ref13-bib13","author":"US Food and Drug Administration","year":"2011"},{"key":"key2026030311253500_ref15-bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/qjmed\/hcv082","article-title":"A national specialized service in England for atypical haemolytic uraemic syndrome-the first year\u2019s experience","volume":"109","author":"Sheerin","year":"2016","journal-title":"QJM"},{"key":"key2026030311253500_ref16-bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Advances in immunology complement (first of two parts)","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"key2026030311253500_ref17-bib17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJM200104123441506","article-title":"Advances in immunology complement (second of two parts)","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"key2026030311253500_ref18-bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/00045632221149660","article-title":"Removal of ethnicity adjustment for creatinine-based estimated glomerular filtration rate equations","volume":"61","author":"Gama","year":"2024","journal-title":"Ann Clin Biochem"},{"key":"key2026030311253500_ref19-bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"key2026030311253500_ref20-bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1740774509105221","article-title":"Bayesian design of single-arm phase II clinical trials with continuous monitoring","volume":"6","author":"Johnson","year":"2009","journal-title":"Clin Trials"},{"key":"key2026030311253500_ref21-bib21","doi-asserted-by":"crossref","first-page":"i115","DOI":"10.1093\/ndt\/gfw353","article-title":"Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome","volume":"32","author":"van den Brand","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"key2026030311253500_ref22-bib22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/13696998.2020.1831519","article-title":"A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome","volume":"23","author":"Wang","year":"2020","journal-title":"J Med Econ"},{"key":"key2026030311253500_ref23-bib23","volume-title":"Company Evidence Submission for Ravulizumab for Treating Atypical Haemolytic Uremic Syndrome (aHUS) [ID1530]","author":"Alexion Pharmaceuticals","year":"2020"},{"key":"key2026030311253500_ref26-bib26","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Michael","year":"2015"},{"key":"key2026030311253500_ref27-bib27","article-title":"A strategy of eculizumab treatment withdrawal with disease monitoring is cost-effective compared to lifelong treatment for eligible atypical haemolytic uraemic syndrome patients: an economic evaluation of the SETS aHUS trial","author":"Orozco-Leal","year":"2025","journal-title":"medRxiv"},{"key":"key2026030311253500_ref28-bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/bmb\/ldu021","article-title":"The economics of medicines optimization: policy developments, remaining challenges and research priorities","volume":"111","author":"Faria","year":"2014","journal-title":"Br Med Bull"},{"key":"key2026030311253500_ref29-bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"PharmacoEconomics"},{"key":"key2026030311253500_ref31-bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"key2026030311253500_ref32-bib32","volume-title":"Qualitative Methods for Health Research","author":"Green","year":"2014"},{"key":"key2026030311253500_ref33-bib33","volume-title":"Strategies of Qualitative Inquiry","author":"Denzin","year":"2013"},{"key":"key2026030311253500_ref34-bib34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1468794104041110","article-title":"Comparing telephone and face-to-face qualitative interviewing: a research note","volume":"4","author":"Sturges","year":"2004","journal-title":"Qual Res"},{"key":"key2026030311253500_ref35-bib35","volume-title":"Methods in Educational Research: From Theory to Practice","author":"Lodico","year":"2006"},{"key":"key2026030311253500_ref36-bib36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1020909529486","article-title":"A purposeful approach to the constant comparative method in the analysis of qualitative interviews","volume":"36","author":"Boeije","year":"2002","journal-title":"Qual Quant"},{"key":"key2026030311253500_ref37-bib37","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fadi","year":"2021","journal-title":"Blood"},{"key":"key2026030311253500_ref38-bib38","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"key2026030311253500_ref39-bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"key":"key2026030311253500_ref40-bib40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood-2017-02-770214","article-title":"Eculizumab cessation in atypical hemolytic uremic syndrome","volume":"130","author":"Merrill","year":"2017","journal-title":"Blood"},{"key":"key2026030311253500_ref41-bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","article-title":"Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update","volume":"66","author":"Ardissino","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"key2026030311253500_ref42-bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/acr.24129","article-title":"Making decisions about stopping medicines for well-controlled juvenile idiopathic arthritis: a mixed-methods study of patients and caregivers","volume":"73","author":"Horton","year":"2021","journal-title":"Arthritis Care Res"},{"key":"key2026030311253500_ref43-bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41927-019-0070-y","article-title":"\u2018Living a normal life\u2019: a qualitative study of patients\u2019 views of medication withdrawal in rheumatoid arthritis","volume":"3","author":"Baker","year":"2019","journal-title":"BMC Rheumatol"},{"key":"key2026030311253500_ref44-bib44","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"key2026030311253500_ref45-bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"key":"key2026030311253500_ref47-bib47","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0000000000004355","article-title":"Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome","volume":"107","author":"Glover","year":"2023","journal-title":"Transplantation"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJNS4701\/GJNS4701.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:25:51Z","timestamp":1772519151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJNS4701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"alternative-id":["10.3310\/GJNS4701"],"URL":"https:\/\/doi.org\/10.3310\/gjns4701","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"09-2017","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"09-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"07-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}